Inventor

Thomas P. Maduskuie, Jr.

Inventor

Wilmington, DE, US

Overview

1992–2021

Patent span

Human necessities

Primary field (CPC A)

Patents· 48 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Dprimary

C07DHeterocyclic compounds41%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations34%

A61KPreparations for medical, dental or toiletry purposes18%

C07CAcyclic or carbocyclic compounds6%

C07BGeneral methods of organic chemistry1%

PatentTitleYear

11,059,8211H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins2021 10,919,912Tricyclic heterocycles as BET protein inhibitors2021 10,781,2091H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins2020 10,646,492Heterocyclylamines as PI3K inhibitors2020 10,472,3581H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins2019 10,464,947Tricyclic heterocycles as BET protein inhibitors2019 10,259,818Bicyclic azaheterocyclobenzylamines as PI3K inhibitors2019 10,092,570Heterocyclylamines as PI3K inhibitors2018 9,957,2681H-pyrrolo[2,3,c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins2018 9,944,646Bicyclic azaheterocyclobenzylamines as PI3K inhibitors2018 9,938,294Tricyclic heterocycles as BET protein inhibitors2018 9,850,257Tricyclic heterocycles as BET protein inhibitors2017 9,815,839'N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors'2017 9,730,939'Heterocyclylamines as PI3K inhibitors'2017 9,624,241'Tricyclic heterocycles as BET protein inhibitors'2017 9,540,368'1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins'2017 9,533,997'Tricyclic heterocycles as BET protein inhibitors'2017 9,527,848'N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors'2016 9,309,251'Bicyclic azaheterocyclobenzylamines as PI3K inhibitors'2016 9,290,514'Tricyclic heterocycles as BET protein inhibitors'2016 9,227,985'Tricyclic heterocycles as bet protein inhibitors'2016 9,096,600'N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors'2015 8,481,732'Substituted heterocyclic compounds'2013 8,415,362'Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors'2013 7,507,815'Succinoylamino lactams as inhibitors of a-Î² protein production'2009 7,304,055'Succinoylamino lactams as inhibitors of AÎ² protein production'2007 7,304,056'Succinoylamino lactams as inhibitors of AÎ² protein production'2007 7,125,870'Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-Î± converting enzyme'2006 7,101,870'Succinoylamino lactams as inhibitors of A-Î² protein production'2006 7,101,883'Uracil derivatives as inhibitors of TNF-Î± converting enzyme (TACE) and matrix metalloproteinases'2006 7,102,008'Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-Î± converting enzyme'2006 6,984,648'Cyclic Î²-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-Î±'2006 6,962,913'Benzo-1,4-diazepin-2-ones as inhibitors of AÎ² protein production'2005 6,794,381'Succinoylamino lactams as inhibitors of a protein'2004 6,743,807'Cyclic -amino acid derivatives as inhibitors of matrix metalloproteases and TNF-'2004 6,620,823'Lactam metalloprotease inhibitors'2003 6,610,731'Lactam metalloprotease inhibitors'2003 6,525,044'Succinoylamino carbocycles and heterocycles as inhibitors of a- protein production'2003 6,521,614'N-(amidinophenyl)cyclourea analogs as factor Xa inhibitors'2003 6,495,565'-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-'2002 6,403,632'Lactam metalloprotease inhibitors'2002 6,057,336'Lactam metalloprotease inhibitors'2000 5,942,544'.alpha.-branched anilines, toluenes, and analogs thereof as factor Xa inhibitors'1999 5,925,635'N-(amidinophenyl) cyclourea analogs as factor XA inhibitors'1999 5,318,984'Imidazoles for the treatment of atherosclerosis'1994 5,179,117'Antihypercholesterolemic 2-substituted imidazoles'1993 5,166,214'Use of imidazoles for the treatment of atherosclerosis'1992 5,095,038'Carbocyclic compounds useful as leukotriene antagonists'1992

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1992–1994Patents assigned to DU PONT MERCK PHARMA (3)· patent assignee history

1992–2021Based in Wilmington, DE, US· patent location history

2002–2009Patents assigned to BRISTOL MYERS SQUIBB PHARMA CO (9)· patent assignee history

2003–2006Patents assigned to BRISTOL MYERS SQUIBB CO (7)· patent assignee history

2013–2021Patents assigned to INCYTE CORP (24)· patent assignee history

2016–2021Patents assigned to INCYTE HOLDINGS CORP (16)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
INCYTE CORP	24	2013–2021
INCYTE HOLDINGS CORP	16	2016–2021
BRISTOL MYERS SQUIBB PHARMA CO	9	2002–2009
BRISTOL MYERS SQUIBB CO	7	2003–2006
DU PONT MERCK PHARMA	3	1992–1994

Locations

Location	Patents	Span
Wilmington, Delaware, US	48	1992–2021